Emergent biological properties of arrestin pathway-selective biased agonism

References

• Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 2006;70:1575–84
   PubMed Web of Science ®Google Scholar
• Maudsley S, Martin B, Luttrell LM. The origins of diversity and specificity in G protein-coupled receptor signaling. J Pharmacol Exp Ther 2005;314:485–94
   PubMed Web of Science ®Google Scholar
• Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 2010;62:305–30
   PubMed Web of Science ®Google Scholar
• Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002;54:323–74
   PubMed Web of Science ®Google Scholar
• Luttrell LM, Kenakin TP. Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol Biol 2011;756:3–35
   Google Scholar
• Maudsley S, Patel SA, Park SS, et al. Functional signaling biases in G protein-coupled receptors: game theory and receptor dynamics. Mini-Rev Med Chem 2012;12:831–40
   Google Scholar
• Appleton KM, Lee M-H, Alele C, et al. Biasing the parathyroid hormone receptor: Relating in vitro ligand efficacy to in vivo biological activity. Methods Enzymol 2013;522:229--62
   Google Scholar
• Kenakin TP. 7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 2009;30:460–9
   PubMed Web of Science ®Google Scholar
• Gesty-Palmer D, Chen M, Reiter E, et al. Distinct conformations of the parathyroid hormone receptor mediate G protein and beta-arrestin dependent activation of ERK1/2. J Biol Chem 2006;281:10856–64
   PubMed Web of Science ®Google Scholar
• Gesty-Palmer D, Flannery P, Yuan L, et al. A beta-arrestin biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 2009;1:1ra1
   PubMed Web of Science ®Google Scholar
• Black JW, Leff P. Operational models of pharmacological agonist. Proc R Soc Lond [Biol] 1983;220:141–62
   PubMed Web of Science ®Google Scholar
• Gesty-Palmer D, Yuan L, Lee M-H, et al. β-Arrestin pathway-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Mol. Endocrinol 2013;27:296--314
   Google Scholar
• Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 2004;15:60–5
   PubMed Web of Science ®Google Scholar
• Mohan S, Kutilek S, Zhang C, et al. Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone 2000;27:471–8
   PubMed Web of Science ®Google Scholar
• Sebastian EM, Suva LJ, Friedman PA. Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone 2008;43:1022–30
   PubMed Web of Science ®Google Scholar
• Deng ZL, Sharff KA, Tang N, et al. Regulation of osteogenic differentiation during skeletal development. Front Biosci 2008;13:2001–21
   PubMed Web of Science ®Google Scholar
• Lian JB, Stein GS, Javed A, et al. Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord 2006;7:1–16
   PubMed Web of Science ®Google Scholar
• Kenakin T, Miller LE. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2012;62:265–304
   Google Scholar
• Rasmussen SG, Choi HJ, Rosenbaum DM, et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007;450:383–7
   PubMed Web of Science ®Google Scholar
• Rasmussen SG, DeVree BT, Zou Y, et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011;477:549–55
   PubMed Web of Science ®Google Scholar
• Yao X, Parnot C, Deupi X, et al. Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol 2006;2:417–22
   PubMed Web of Science ®Google Scholar
• Ballesteros JA, Jensen AD, Liapakis G, et al. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001;276:29171–7
   PubMed Web of Science ®Google Scholar
• Oldham WM, Hamm HE. How do receptors activate G proteins?. Adv Protein Chem 2007;74:67–93
   PubMedGoogle Scholar
• Yao XJ, Vélez Ruiz G, Whorton MR, et al. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci USA 2009;106:9501–6
   PubMed Web of Science ®Google Scholar
• Liu JJ, Horst R, Katritch V, et al. Biased signaling pathways in ®2-adrenergic receptor characterized by 19F-NMR. Science 2012;335:1106–10
   PubMed Web of Science ®Google Scholar
• Coulon V, Audet M, Homburger V, et al. Subcellular imaging of dynamic protein interactions by bioluminescence resonance energy transfer. Biophys J 2008;94:1001–9
   PubMed Web of Science ®Google Scholar
• Saulière A, Bellot M, Paris H, et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat Chem Biol 2012;8:622–30
   PubMed Web of Science ®Google Scholar
• Wei H, Ahn S, Shenoy SK, et al. Independent G protein and beta-arrestin2 mediated activation of ERK by angiotensin. Proc Natl Acad Sci USA 2003;100:10782–7
   PubMed Web of Science ®Google Scholar
• Azzi M, Charest PG, Angers S, et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 2003;100:11406–11
   PubMed Web of Science ®Google Scholar
• Rajagopal K, Whalen EJ, Violin JD, et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 2006;103:16284–9
   PubMedGoogle Scholar
• Aplin M, Christensen GL, Schneider M, et al. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin Pharmacol Toxicol 2007;100:296–301
   PubMed Web of Science ®Google Scholar
• Kendall RT, Strungs EG, Rachidi SM, et al. The b-arrestin pathway-selective angiotensin AT1A receptor agonist, Sar1Ile4Ile8-AngII, regulates a robust G protein-independent signaling network. J Biol Chem 2011;286:19880–91
   PubMedGoogle Scholar
• Christensen GL, Kelstrup CD, Lyngsø C, et al. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteom 2010;9:1540–53
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Quarti-Trevano F, Dell'oro R. Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications. Curr Vasc Pharmacol 2009;7:137–45
   PubMedGoogle Scholar